Fyi, it’s world sepsis day. The toxic condition cost $14.6 billion according to 2008 stats from the Centers for Disease Control and several companies and hospitals are looking for effective ways to combat the infection or identify it in its early stages. Cytosorbents developed a filtration system for the condition. It’s signed an agreement for a new strategic partner, Biocon, to bring its sepsis treatment to market in India, according to a company statement.
Sepsis is the 11th leading cause of death in the world and it’s a significant problem in India where it’s estimated that more than one million new cases of severe sepsis are treated in intensive care units each year.
The company’s name derives from cytokines — proteins that help regulate the immune system. But in excess amounts these cytokines can be harmful and cause organ failure referred to as a cytokine storm. To make matters worse, it tends to be a bigger risk in vulnerable patients in hospital intensive care units.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company’s Cytosorb filtration system is designed to remove excess amounts of the protein from the body. It also sees applications beyond sepsis such as pancreatitis and liver failure.
Cytosorbents has been in expansion mode since it received CE mark approval from European regulators in 2011.
Since then it has marketed the medical device in Germany, Austria, Switzerland and most recently in the UK. It’s currently seeking FDA clearance for the device.
